Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analytical approach

被引：0
|
作者：
Grossi, Francesco
Belvedere, Ornella
Defferrari, Carlotta
Rosetti, Francesco
Vinante, Orazio
Pappagallo, Giovanni
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Udine, I-33100 Udine, Italy
[3] Osped PF Calvi, Noale, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [41] Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
    Alessi, J.
    Elkrief, A.
    Ricciuti, B.
    Cortellini, A.
    Wang, X.
    Vaz, V. R.
    Barrichello, A.
    Lamberti, G.
    Fulgenzi, C.
    Pecci, F.
    Pinato, D. J.
    Schoenfeld, A. J.
    Awad, M. M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S358 - S359
  • [42] Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer
    Garcia-Fumero, Ricardo
    Fernandez-Lopez, Cristina
    Calleja-Hernandez, Miguel angel
    Exposito-Ruiz, Manuela
    Espin, Jaime
    Exposito-Hernandez, Jose
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (10): : 433 - 438
  • [43] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [44] Meta-analysis of pemetrexed (P) plus gemcitabine (G) in first-line, advanced (adv) non-small cell lung cancer (NSCLC)
    Ye, Z.
    Treat, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [46] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [47] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
  • [48] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
  • [49] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G. W.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
  • [50] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Jaime, B. Moreno
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
12345